{
    "root": "00f58c32-e17f-472d-8499-2e9d974146c3",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Cyclobenzaprine Hydrochloride",
    "value": "20250312",
    "ingredients": [
        {
            "name": "CYCLOBENZAPRINE HYDROCHLORIDE",
            "code": "0VE05JYS2P"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions.\n                  Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living.\n                  \n                     Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. \n                  \n                  Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy.",
    "contraindications": "For most patients, the recommended dose of cyclobenzaprine hydrochloride tablets is 5 mg three times a day. Based on individual patient response, the dose may be increased to 10 mg three times a day. Use of cyclobenzaprine hydrochloride tablets for periods longer than two or three weeks is not recommended (see INDICATIONS AND USAGE). \n                  Less frequent dosing should be considered for hepatically impaired or elderly patients (see PRECAUTIONS:  Impaired Hepatic Function, and Use in the Elderly).",
    "warningsAndPrecautions": "Cyclobenzaprine Hydrochloride Tablets, USP are available in the following strength and package sizes: \n                  7.5 mg (White, round, film coated tablets, debossed with “C 735” on one side and plain on the other side)\n                  Bottle of  8 - 68788-9967-7\n                  Bottle of 20 - 68788-9967-2\n                  Bottle of 30 - 68788-9967-3\n                  Bottle of 60 - 68788-9967-6\n                  Bottle of 90 - 68788-9967-9\n                  Bottle of 100 - 68788-9967-1\n                  Bottle of 120 - 68788-9967-8\n                  \n                     Store at 20º to 25°C (68º to 77°F) [See USP Controlled Room Temperature].\n                  \n                  Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.\n                  \n                     Manufactured for: \n                  \n                  SA3, LLCLos Angeles, CA 90064\n                  Rev. # 09/2019\n                  \n                     Repackaged By: Preferred Pharmaceuticals Inc.",
    "adverseReactions": "Hypersensitivity to any component of this product. \n                  Concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after their discontinuation. Hyperpyretic crisis seizures, and deaths have occurred in patients receiving cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitor drugs. \n                  Acute recovery phase of myocardial infarction, and patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure. \n                  Hyperthyroidism."
}